US generic drugmaker ANI Pharmaceuticals (Nasdaq: ANIP) says it has acquired the US rights for the antibiotic Vancocin (vancomycin HCl) 125mg and 250mg capsules from Shire (LSE: SHP), the Ireland-based pharma company that has just succumbed to a $53 billion takeover offer from AbbVie (NYSE: ABBV).
In addition, ANI acquired from Shire approved Abbreviated New Drug Applications for the currently non-marketed products vancomycin injectable 500mg, 1gm and 10gm ($45 million in 2013 market value, per IMS Health) and vancomycin oral solution 250mg and 500mg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze